A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies.

[1]  C. Hudis,et al.  Invasive breast cancer version 1.2016 , 2016 .

[2]  Re: Eric A. Klein, Matthew R. Cooperberg, Cristina Magi-Galluzzi, et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur urol 2014;66:550-60. , 2014, European urology.

[3]  P. Febbo,et al.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.

[4]  R. Figlin,et al.  Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma , 2014, Cancer Chemotherapy and Pharmacology.

[5]  G. Bratslavsky,et al.  Compared with radical nephrectomy, nephron-sparing surgery offers a long-term survival advantage in patients between the ages of 20 and 44 years with renal cell carcinomas (≤4 cm): an analysis of the SEER database. , 2014, Urologic oncology.

[6]  M. Kattan,et al.  ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.

[7]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[8]  H. Hieronymus,et al.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.

[9]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[10]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  S. Welsh,et al.  Adjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future☆ , 2013, Seminars in oncology.

[12]  B. Rini,et al.  Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone , 2013, Anti-cancer drugs.

[13]  A. Belldegrun,et al.  ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials. , 2013 .

[14]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[15]  A. Belldegrun,et al.  Systemic therapy for metastatic renal cell carcinoma: a review and update. , 2012, Reviews in urology.

[16]  W. Marston Linehan,et al.  Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors , 2011, PLoS genetics.

[17]  B. Delahunt,et al.  Grading of Clear Cell Renal Cell Carcinoma Should be Based on Nucleolar Prominence , 2011, The American journal of surgical pathology.

[18]  S. Paik,et al.  Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  N. Rioux-Leclercq,et al.  Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. , 2010, Urology.

[20]  C. Compton,et al.  The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM , 2010, Annals of Surgical Oncology.

[21]  Gyan Bhanot,et al.  Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. , 2010, Genes & cancer.

[22]  Michael R Crager,et al.  Gene identification using true discovery rate degree of association sets and estimates corrected for regression to the mean , 2009, Statistics in medicine.

[23]  Soonmyung Paik,et al.  Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.

[24]  A. Belldegrun,et al.  Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. , 2009, The Journal of urology.

[25]  K. Bensalah,et al.  A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. , 2009, European urology.

[26]  Ying Huang,et al.  A three‐gene expression signature model to predict clinical outcome of clear cell renal carcinoma , 2008, International Journal of Cancer.

[27]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Cronin,et al.  Biomarker discovery for colon cancer using a 761 gene RT-PCR assay , 2007, BMC Genomics.

[29]  J. Mclaughlin,et al.  The epidemiology of renal cell carcinoma. , 2006, The Journal of urology.

[30]  F. Ito,et al.  Favorable prognosis of renal cell carcinoma with increased expression of chemokines associated with a Th1‐type immune response , 2006, Cancer science.

[31]  J. Cheville,et al.  Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness , 2005, Cancer.

[32]  J. Cheville,et al.  Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness , 2005, Clinical Cancer Research.

[33]  Matteo Brunelli,et al.  Original and reviewed nuclear grading according to the Fuhrman system , 2005, Cancer.

[34]  M. Kattan,et al.  A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. , 2005, The Journal of urology.

[35]  W. Rathmell,et al.  Renal cell carcinoma , 2007, Current opinion in oncology.

[36]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[37]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[38]  J. Blay,et al.  Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Horita,et al.  High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. , 2004, The Journal of urology.

[40]  Debjani Dutta,et al.  Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. , 2004, The American journal of pathology.

[41]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[42]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[43]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[44]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[46]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[47]  C. Bokemeyer,et al.  Chemotherapy for renal cell carcinoma. , 1999, Anticancer research.

[48]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[49]  S. Fuhrman,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 1982, The American journal of surgical pathology.